KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $5.3 million.

  • Halozyme Therapeutics' Non Operating Income fell 1762.43% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 million, marking a year-over-year increase of 2029.37%. This contributed to the annual value of $23.8 million for FY2024, which is 4556.6% up from last year.
  • Halozyme Therapeutics' Non Operating Income amounted to $5.3 million in Q3 2025, which was down 1762.43% from $6.9 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Non Operating Income ranged from a high of $7.3 million in Q4 2024 and a low of -$945000.0 during Q2 2022
  • Its 5-year average for Non Operating Income is $3.2 million, with a median of $3.2 million in 2023.
  • Its Non Operating Income has fluctuated over the past 5 years, first tumbled by 52760.18% in 2022, then soared by 64664.59% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Non Operating Income (Quarter) stood at $331000.0 in 2021, then soared by 157.4% to $852000.0 in 2022, then soared by 529.11% to $5.4 million in 2023, then surged by 35.32% to $7.3 million in 2024, then dropped by 26.47% to $5.3 million in 2025.
  • Its Non Operating Income stands at $5.3 million for Q3 2025, versus $6.9 million for Q2 2025 and $6.8 million for Q1 2025.